Joseph Tuscano

This study is testing a new two-step treatment for people with a high-risk type of aggressive lymphoma who haven't had treatment before. First, patients receive a targeted drug combination designed to seek out and kill cancer cells. This is followed by a standard, but intensive, …

This study is testing whether adding a new drug called odronextamab to standard CAR-T cell therapy works better for aggressive lymphoma. It will involve about 34 adults whose lymphoma has come back or hasn't responded to at least two prior treatments. The goal is to see if giving…

This study is testing whether adding a new immune-boosting drug called epcoritamab to standard chemotherapy and a stem cell transplant can better control aggressive large B-cell lymphoma that has returned or not responded to prior treatment. It will involve about 25 adults whose …